The National Institute of Dental and Craniofacial Research at the National Institutes of Health Clinical Center in Bethesda, Maryland, is conducting a research study to evaluate the usefulness, safety, and tolerability of a drug called rapamycin. Researchers are investigating the effect of this drug for the treatment of head and neck cancer prior to surgery. This research study requires approximately eight visits for initial evaluation, testing, and treatment. The number of additional visits will be determined based on the care physicians recommended.
You may qualify if you:
- Are 18 or older
- Have a diagnosis of advanced oral cavity cancer
You may not qualify if you:
- Had prior head and neck cancer except for previously treated skin cancer
- Prior received chemotherapy or radiation
- Hepatitis B or C
- Received a vaccination for measles, mumps, rubella, oral polio, varicella, yellow fever, typhoid, or influenza in the past 30 days
For more information, please call toll free:
1-800-411-1222
TTY: 1-866-411-1010
Se habla español
Or go online:
clinicaltrials.gov
Refer to study #10-D-0180
Department of Health and Human Services
National Institutes of Health
National Institute of Dental and Craniofacial Research
NOTE: PDF documents require the free Adobe Reader.